e
:
en
z
erung un
Charakterisierun
von Leukämie-
spezifischen T-Zellen (PM30)
Projektpartner:
.
,
Prof. Dr. med. Angela Krackhardt und
www.m4.de
Aims
• Identification/Isolation of T cells in ATIR™ responsible for graft versus
ATIR/post-transplant donor T cells
Leukemia‐peptide
Co-incubation with peptide
pulsed recipient LCL or HLA-
tr
n
ni
ll lin
production
AG Busch, TUM
HLA monomer
IFN-γ
capture
ELISpot
www.m4.de
Results: ATIR™
hase I/II clinical trial
donor
ATIR: Personalized T-cell product, depleted of allo-reactive T cells
Leukoc
te collection
Activation
Personalized
patient
TH942
Allo-reactive
Light
Activation of
of allo-
reactive
T-cells in
one-way
MLR
-ce
product
ATIR
Infusion of
ATIR four
weeks after
Gamma
irradiation
patient
T-cells
incorporate
novel
compound
TH9402
TH9402 by
light results
in depletion
of allo-
reactive
T-cells
Transplant related mortality
HSCT
ATIR:
60% patients active disease
at HSCT
Naked haplo:
All patients in remission
www.m4.de
Results: Reactivit
of ATIR™
roduct
donor
Recipient
alloreactive
Other
T-cells
3rd party
alloreactive
ATIR
Donor
Viral
reactive
ATIR
Leukemia
reactive
www.m4.de
Comments to this Manuals